Business
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 – - Brilaroxazine topical liposomal-gel formulation
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 – - Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model – - IND submission for brilaroxazine lipogel in psoriasis expected in 2024 - CUPERTINO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today reported financial results for the first quarter ended March 31, 2023 and summarized recent business highlights. “We started off 2023 focused on maximizing the broad therapeutic potential of brilaroxazine and executing across our important milestones in the year ahead. With the completion of several clinical and nonclinical prelaunch studies to support our potential new drug application (NDA) submission for brilaroxazine in schizophrenia, we believe we are well-positioned for topline Phase 3 data from our RECOVER trial expected mid-year,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “We were also pleased to recently present new preclinical data at ISID for our novel topical formulation of brilaroxazine, brilaroxazine lipogel, demonstrating promising potential for the treatment of psoriasis. We have filed patents for this formulation and its use in psoriasis and intend to submit an investigational new drug application (IND) for brilaroxazine lipogel in psoriasis in 2024 to further explore this therapeutic potential.” First Quarter 2023 Highlights and Recent Business Highlights Corporate Highlights Presented on the liposomal-gel formulation of brilaroxazine and potential in psoriasis at the International Societies for Investigative Dermatology (ISID) Meeting (May 2023)Hosted key opinion leader webinar on brilaroxazine for the treatment of schizophrenia, featuring a presentation by Larry Ereshefsky, PharmD (Follow the Molecule LLC) (May 2023)Presented foundational preclinical data on brilaroxazine in schizophrenia at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) and publication in Medical Research Archives (May 2023)...